Biodesix, Inc. BDSX 深 滬
已收盤 02-06 16:00:00 美东时间
10.38
+0.420
+4.22%
華盛通- 最 高10.84
- 今 開10.10
- 成交量 8.31万股
- 最 低 9.95
- 昨 收 9.96
- 總市值 8258.00万
- 52周最高 20.40
- 市盈率 靜 --
- 換手率 1.04%
- 52周最低 3.436
- 委 比 -93.75%
- 總股本 795.57万
- 歷史最高 639.80
- 量 比 0.55
- 振 幅 8.94%
- 歷史最低 3.436
- 每 手 1
- 風險率 3.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jack W. Schuler, 10% Owner, Acquires Common Shares of Biodesix Inc
Jack W. Schuler, 10% Owner, Acquires Common Shares of Biodesix Inc Jack W. Schuler, a 10% Owner and Emeritus Director, reported the acquisition of common shares of Biodesix Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PU
01-26 22:29
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers PAVmed (NASDAQ:PAVM) stock increased by 250.7% to $21.71 during Wednes...
01-22 01:05
Biodesix shares are trading higher after the company reported a year-over-year increase in Q4 and FY25 revenue results.
Biodesix shares are trading higher after the company reported a year-over-year ...
01-13 00:03
Market-Moving News for January 12th
XOM: -1.5% | Trump 'Inclined' To Keep Exxon Mobil Out Of Venezuela: 'Didn't Like Their Response' BDSX: 46% | Biodesix Sees Q4 Revenue $28.8M, FY2025 Revenue $88.5M, Up 41% and 24% YoY CRML: 15% |
01-12 20:29
Biodesix skyrockets 43%, expects FY revenue to beat guidance
Precision diagnostics company Biodesix (BDSX) stock price climbed 41% on Monday during pre-market hours of trading as the company reported its preliminary Q4 and FY numbers, expecting a 24% jump to FY...
01-12 20:17
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
Biodesix, Inc. reported preliminary financial results for Q4 and FY 2025, with estimated revenue of $28.8M (41% YOY growth) for Q4 and $88.5M (24% YOY growth) for the full year. Lung Diagnostics revenue grew 47% and 22% for Q4 and FY 2025, respectively, driven by increased test volumes and reimbursement. Development Services revenue increased 13% and 41% for Q4 and FY 2025. Cash and cash equivalents reached $19.0M as of December 31, 2025, a 14% i...
01-12 11:00
Biodesix To Present Data On Development Of New Ultra-Sensitive ESR1 Test For Initial Detection And Monitoring Of Mutations In HR+/HER2- Advanced Breast Cancers At SABCS
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.The
2025-12-03 21:28
Biodesix Q3 EPS $(1.16) Beats $(1.45) Estimate, Sales $21.768M Beat $20.974M Estimate
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(1.16) per share which beat the analyst consensus estimate of $(1.45) by 20 percent. This is a 17.14 percent increase over losses of $(1.40) per share from the same
2025-11-04 05:42
Biodesix Raises FY2025 Sales Guidance from $80.000M-$85.000M to $84.000M-$86.000M vs $83.236M Est
Biodesix (NASDAQ:BDSX) raises FY2025 sales outlook from $80.000 million-$85.000 million to $84.000 million-$86.000 million vs $83.236 million estimate.
2025-11-04 05:04
